The width and depth of clinical trials have also dramatically improved in an unprecedented speed The personalized treatment paradigm evolved every year In this review, we summarize the promising agents that have shifted the treatment paradigm for nsclc patients. This review by members of the committee highlights the breadth of current research in nsclc, with a focus on molecular risk factors and processes in tumorigenesis, heterogeneity, phenotypic plasticity, metabolic reprogramming, immunobiology, the immune microenvironment, and microbiome. Tyrosine kinase inhibitors targeting oncogenic driver mutations continue to evolve over multiple generations to enhance effectiveness and tackle drug resistance Immune checkpoint inhibitors remain integral for the treatment of nsclcs that do not have specific actionable.
Food and drug administration and the center for drug evaluation in china granted bay 2927088 breakthrough therapy designation in 2024 for the treatment of adult patients with. External validation in a trial with dostarlimab [abstract] Proceedings of the american association for cancer research annual meeting 2025
WATCH
